Cocrystal Pharma, Inc.
$1.51
▲
48.04%
2026-04-21 06:09:00
www.cocrystalpharma.com
NCM: COCP
Explore Cocrystal Pharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$20.82 M
Current Price
$1.51
52W High / Low
$2.67 / $0.86
Stock P/E
—
Book Value
$0.46
Dividend Yield
—
ROCE
-120.22%
ROE
-1.11%
Face Value
—
EPS
$-0.78
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
10
Beta
1.18
Debt / Equity
23.77
Current Ratio
3.68
Quick Ratio
3.68
Forward P/E
-1.95
Price / Sales
—
Enterprise Value
$11.71 M
EV / EBITDA
-1.31
EV / Revenue
—
Rating
Strong Buy
Target Price
$8
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Axsome Therapeutics, Inc. | $184.13 | — | $9.35 B | — | -54.42% | -2.52% | $191.5 / $96.09 | $1.74 |
| 2. | Protara Therapeutics, Inc. | $5.3 | — | $286.65 M | — | -32.51% | -31.6% | $7.82 / $2.77 | $3.67 |
| 3. | Fate Therapeutics, Inc. | $1.39 | — | $158.12 M | — | -52.22% | -51.84% | $1.94 / $0.91 | $1.8 |
| 4. | Vir Biotechnology, Inc. | $11.09 | — | $1.72 B | — | -52.69% | -45.73% | $10.94 / $4.16 | $5.49 |
| 5. | Caribou Biosciences, Inc. | $2.29 | — | $212.6 M | — | -90.82% | -78.97% | $3.54 / $0.71 | $1.28 |
| 6. | Spyre Therapeutics, Inc. | $73.39 | — | $5.76 B | — | -30.53% | -25.17% | $75 / $12.25 | $7.16 |
| 7. | Avalo Therapeutics, Inc. | $14.66 | — | $334.08 M | — | -70.45% | -72.44% | $20.72 / $3.39 | $4.49 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -2.48 M | -2.09 M | -2.11 M | -2.34 M | -3.23 M | — |
| Net Profit | -2.43 M | -2.05 M | -2.06 M | -2.3 M | -3.27 M | — |
| EPS in Rs | -0.18 | -0.15 | -0.15 | -0.17 | -0.24 | -0.49 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -9.02 M | -17.88 M | -21.16 M | -18.14 M |
| Net Profit | -8.83 M | -17.5 M | -17.98 M | -38.84 M |
| EPS in Rs | -0.64 | -1.27 | -1.3 | -2.82 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 9.71 M | 13.46 M | 31.26 M | 40.84 M |
| Total Liabilities | 3.38 M | 3.93 M | 4.88 M | 1.27 M |
| Equity | 6.33 M | 9.52 M | 26.38 M | 39.57 M |
| Current Assets | 8.13 M | 11.58 M | 29.09 M | 40.18 M |
| Current Liabilities | 2.21 M | 2.43 M | 3.26 M | 1.22 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -8.19 M | -16.48 M | -14.67 M | -21.43 M |
| Investing CF | -0.01 M | -0.01 M | -0.12 M | -0.07 M |
| Financing CF | 5.37 M | 0 M | 3.99 M | -0.03 M |
| Free CF | -8.2 M | -16.49 M | -14.78 M | -21.51 M |
| Capex | -0.01 M | -0.01 M | -0.12 M | -0.07 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 2.67% | 53.69% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2022-10-11 | 1:0.0833333 |